Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer.

PURPOSE The role played by the innate immune system in determining survival from non-small-cell lung cancer (NSCLC) is unclear. The aim of this study was to investigate the prognostic significance of macrophage and mast-cell infiltration in NSCLC. METHODS We used immunohistochemistry to identify tryptase+ mast cells and CD68+ macrophages in the tumor stroma and tumor islets in 175 patients with surgically resected NSCLC. RESULTS 5-year survival was 52.9% in patients with an islet macrophage density greater than the median versus 7.7% when less than the median (P < .0001). In the same groups, respectively, median survival was 2,244 versus 334 days (P < .0001). Patients with a high islet macrophage density but incomplete resection survived markedly longer than patients with a low islet macrophage density but complete resection. CONCLUSION The tumor islet CD68+ macrophage density is a powerful independent predictor of survival from surgically resected NSCLC. The biologic explanation for this and its implications for the use of adjunctive treatment requires further study.

[1]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Bengt Bergman,et al.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.

[3]  G. Soma,et al.  The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. , 2003, Anticancer research.

[4]  S. Abe,et al.  Chymase-positive mast cells in small sized adenocarcinoma of the lung , 2003, Virchows Archiv.

[5]  Jeremy J. W. Chen,et al.  Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  E. Kay,et al.  Infiltrating immune cells, but not tumour cells, express FasL in non‐small cell lung cancer: No association with prognosis identified in 3‐year follow‐up , 2003, International journal of cancer.

[7]  Noam Brown,et al.  The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies , 2002, The Journal of pathology.

[8]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 1995. , 2002, European journal of cancer.

[9]  K J O'Byrne,et al.  Chronic immune activation and inflammation as the cause of malignancy , 2001, British Journal of Cancer.

[10]  T. Wheeler,et al.  Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. , 2000, Cancer research.

[11]  I. Takanami,et al.  Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma , 2000, Cancer.

[12]  H. Kojima,et al.  Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. , 2000, The European respiratory journal.

[13]  K. Kerr,et al.  Immune cell infiltrates and prognosis in primary carcinoma of the lung. , 2000, Lung cancer.

[14]  I. Takanami,et al.  Tumor-Associated Macrophage Infiltration in Pulmonary Adenocarcinoma: Association with Angiogenesis and Poor Prognosis , 1999, Oncology.

[15]  K. O'Byrne,et al.  Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival. , 1998, British Journal of Cancer.

[16]  N. Freudenberg,et al.  Infiltration of lung carcinomas with macrophages of the 27E10-positive phenotype. , 1997, Lung cancer.

[17]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[18]  M. Koutsilieris,et al.  Mast cell-tumor cell interactions: for or against tumour growth and metastasis? , 1997, Anticancer research.

[19]  K. Mahnke,et al.  Heterodimers of the calcium‐binding proteins MRP8 and MRP14 are expressed on the surface of human monocytes upon adherence to fibronectin and collagen. Relation to TNF‐α, IL‐6, and superoxide production , 1995, Journal of leukocyte biology.

[20]  P. Howarth,et al.  Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. , 1994, American journal of respiratory cell and molecular biology.

[21]  S. Pileri,et al.  PG-M1: a new monoclonal antibody directed against a fixative-resistant epitope on the macrophage-restricted form of the CD68 molecule. , 1993, The American journal of pathology.

[22]  S. Holgate,et al.  Production and characterization of monoclonal antibodies specific for human mast cell tryptase , 1990, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.